Literature DB >> 26093347

Effect of different doses of zoledronic acid in establishing of bisphosphonate-related osteonecrosis.

Paulo Goberlânio de Barros Silva1, Antonio Ernando Carlos Ferreira Junior2, Carolina Rodrigues Teófilo2, Maritza Cavalcante Barbosa3, Roberto César Pereira Lima Júnior4, Fabrício Bitú Sousa2, Mário Rogério Lima Mota2, Ronaldo de Albuquerque Ribeiro4, Ana Paula Negreiros Nunes Alves2.   

Abstract

OBJECTIVES: To establish osteonecrosis of the jaws in rats treated with different doses of zoledronic acid (ZA).
METHODS: Male Wistar rats (n=6-7) received three consecutive weekly intravenous ZA infusions at doses of 0.04, 0.20 or 1.00mg/kg ZA or saline (control). Four weeks after the last administration, the animals were submitted to simple extraction of the lower left first molar. An additional dose of ZA was administered seven days later, and the animals were sacrificed 28 days after exodontia. Weight was measured and blood was collected weekly for analysis. The jaw was radiographically and microscopically examined along with the liver, spleen, kidney and stomach.
RESULTS: All ZA doses showed a higher radiolucent area than the control (p<0.0001), but the dose of 0.04mg/kg did not show BRONJ. Doses of 0.20 and 1.00mg/kg ZA showed histological evidence of bone necrosis (p=0.0004). Anaemia (p<0.0001, r(2)=0.8073) and leucocytosis (p<0.0001, r(2)=0.9699) are seen with an increase of lymphocytes (p<0.0001, r(2)=0.6431) and neutrophils and monocytes (p=0.0218, r(2)=0.8724) in all the animals treated with an increasing dose of ZA. Haemorrhage and ectasia were observed in the spleen (p=0.0004) and stomach (p=0.0168) in a dose-dependent manner, and the animals treated with ZA showed a lower rate of weight gain (p<0.0001).
CONCLUSIONS: We designed a bisphosphonate-related osteonecrosis of the jaw model that reproduces radiographic and histological parameters and mimics clinical alterations such as leucocytosis, anaemia and idiosyncratic inflammatory post infusion reactions.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute-phase reaction; Anaemia; Bisphosphonate-associated osteonecrosis of the jaw; Leukocytosis; Zoledronic acid

Mesh:

Substances:

Year:  2015        PMID: 26093347     DOI: 10.1016/j.archoralbio.2015.05.015

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  13 in total

1.  Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy.

Authors:  Valesca S Koth; Maria A Figueiredo; Fernanda G Salum; Karen Cherubini
Journal:  Dentomaxillofac Radiol       Date:  2017-02-17       Impact factor: 2.419

2.  Volumetric analysis of the periodontal microstructure under antiresorptive therapy: an experimental study in rabbits.

Authors:  Kathrin Becker; Robert Kerberger; Giulia Brunello; Joel Rockhoff; Nicole Rauch; Frank Schwarz
Journal:  Clin Oral Investig       Date:  2022-04-22       Impact factor: 3.606

Review 3.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

4.  Treatment of bisphosphonate-related osteonecrosis of the jaws - a report of seven cases.

Authors:  Joanna Jakiel; Mansur Rahnama; Joanna Szczerba-Gwóźdź
Journal:  Contemp Oncol (Pozn)       Date:  2017-01-12

5.  Application of Autologous Platelet-Rich Plasma on Tooth Extraction Site Prevents Occurence of Medication-Related Osteonecrosis of the Jaws in Rats.

Authors:  Luan Felipe Toro; João Martins de Mello-Neto; Fernanda Furuse Ventura Dos Santos; Letícia Chaves Ferreira; Cristian Statkievicz; Luciano Tavares Ângelo Cintra; João Paulo Mardegan Issa; Rita Cássia Menegati Dornelles; Juliano Milanezi de Almeida; Maria José Hitomi Nagata; Valdir Gouveia Garcia; Leticia Helena Theodoro; Cláudio Aparecido Casatti; Edilson Ervolino
Journal:  Sci Rep       Date:  2019-01-10       Impact factor: 4.379

6.  The effect of high concentration of zoledronic acid on tooth induced movement and its repercussion on root, periodontal ligament and alveolar bone tissues in rats.

Authors:  Fátima Regina Nunes de Sousa; Vanessa Costa de Sousa Ferreira; Conceição da Silva Martins; Hugo Victor Dantas; Frederico Barbosa de Sousa; Virgínia Cláudia Carneiro Girão-Carmona; Paula Goes; Gerly Anne de Castro Brito; Renata Ferreira de Carvalho Leitão
Journal:  Sci Rep       Date:  2021-04-07       Impact factor: 4.379

7.  Clinical efficacy of zoledronic acid combined with percutaneous kyphoplasty in the prevention and treatment of osteoporotic vertebral compression fracture: A systematic review and meta-analysis.

Authors:  Kaiming Li; Hao Gong; Rui Xie; Jinyu Gu; Shangquan Wang; Chengyu Lin; Jing Yin; Xiaozhou Hou; Qing Zhang; Linghui Li; Yanke Hao
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

8.  Evaluation of a collagen matrix in a mandible defect in rats submitted to the use of bisphosphonates.

Authors:  Vanessa Vasconcelos Cunha; Paulo Goberlânio de Barros Silva; José Vitor Mota Lemos; Joyce Ohana Lima Martins; Milena Oliveira Freitas; Rafael Linard Avelar
Journal:  Acta Cir Bras       Date:  2020-11-30       Impact factor: 1.388

9.  Relationship between disease stage and renal function in bisphosphonate-related osteonecrosis of the jaw.

Authors:  Yun-Ho Kim; Han-Kyul Park; Na-Rae Choi; Seong-Won Kim; Gyoo-Cheon Kim; Dae-Seok Hwang; Yong-Deok Kim; Sang-Hun Shin; Uk-Kyu Kim
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2017-02-20

10.  Tocilizumab, a Potent Interleukin-6 Receptor Inhibitor, Decreases Bone Resorption and Increases the Rate of Bacterial Infection After Tooth Extraction in Rats.

Authors:  Maria Imaculada de Queiroz Rodrigues; Joyce Ohana de Lima Martins; Paulo Goberlânio de Barros Silva; Antônio Ernando Carlos Ferreira Júnior; Maria Elisa Quezado Lima Verde; Fabrício Bitú Sousa; Mário Rogério Lima Mota; Ana Paula Negreiros Nunes Alves
Journal:  J Oral Maxillofac Surg       Date:  2020-08-15       Impact factor: 1.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.